Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of FCN-207 in Healthy Volunteers
NCT04622124Phase 1Completed
- Sponsor
- Fochon Biosciences
- Start
- Nov 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FCN-207 in hyperuricemia (5 arms), sponsored by Fochon Biosciences. Primary endpoints: Occurrence of adverse events, Occurrence of treatment-emergent adverse events and 1 more. Started Nov 2020; status: completed.
02
Drugs
FCN-207
03
Conditions
hyperuricemia
Beyond the preview
Go deeper on NCT04622124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622124.